68223-99-4

Basic information

• Product Name: 1-allyloxy-2-bromo-4-methoxybenzene
• Synonyms: 1-allyloxy-2-bromo-4-methoxybenzene
• CAS NO: 68223-99-4
• Molecular Weight: 243.1
• Mol File: 68223-99-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-allyloxy-2-bromo-4-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-allyloxy-2-bromo-4-methoxybenzene(68223-99-4)
• EPA Substance Registry System: 1-allyloxy-2-bromo-4-methoxybenzene(68223-99-4)

Safety Data

• Hazardous Substances Data: 68223-99-4(Hazardous Substances Data)

Upstream product

• 150-76-5 4-methoxy-phenol 
• 17332-11-5 2-bromo-4-methoxyphenol 
• 106-95-6 allyl bromide 

Relevant articles and documents

Cali xanthene mycin A glycosyl ligand and intermediates and preparation method thereof

The invention discloses cali xanthene mycin A glycosyl ligand and intermediates and a preparation method thereof. The chemical construction of the cali xanthene mycin A glycosyl ligand is shown in formula 1, the preparation of the cali xanthene mycin A gl

1-Aminomethylbenzocycloalkanes: Conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists

A series of conformationally restricted analogues of the hallucinogenic phenethylamine 1 (2,5-dimethoxy-4-bromophenethylamine, 2C-B) was synthesized to test several hypotheses concerning the bioactive conformation of phenethylamine ligands upon binding to the 5-HT2A receptor. These benzocycloalkane analogues were assayed for their receptor binding affinity and ability to activate downstream signaling pathways, and one exceptional compound was selected for testing in an in vivo drug discrimination model of hallucinogenesis. All compounds were examined in silico by virtual docking into a homology model of the 5-HT2A receptor. On the basis of these docking experiments, it was predicted that the R enantiomer of benzocyclobutene analogue 2 would be the most potent. Subsequent chemical resolution and X-ray crystallography confirmed this prediction, as (R)-2 proved to be equipotent to LSD in rats trained to discriminate LSD from saline. Thus, we propose that the conformation of 2 mimics the active binding conformation of the more flexible phenethylamine type hallucinogens. In addition, (R)-2 is one of the most potent and selective compounds yet discovered in the in vivo drug discrimination assay. Further, 2 was found to be a functionally selective agonist at the 5-HT 2A receptor, having 65-fold greater potency in stimulating phosphoinositide turnover than in producing arachidonic acid release. If hallucinogenic effects are correlated with arachidonic acid production, such functionally selective 5-HT2A receptor agonists may lack the intoxicating properties of hallucinogens such as LSD.